Aktienanalyse zu DarioHealth Corp (DRIO)DRIODarioHealth Corp

DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

DarioHealth Corp is currently not a strong buy due to its low price of $6.77 and the RSI of 31.444, indicating oversold conditions. The company has shown reduced losses, with a net loss of $7.92 million in Q2, down from $18.56 million last year, and a gross margin of 61.66%. However, the hedge funds are selling, with a 109.67% increase in selling activity over the last quarter, which raises concerns about future performance.

2 analysts cover DRIO: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 13.50.